Methods for treating viral disorders

1. A method for treating neoplasia associated with Epstein-Barr virus infection in a subject, comprising administering to the subject an inducing agent to induce expression of a viral gene product in a virus-infected cell of the subject and an anti-viral agent whose anti-viral activity is directed to the viral gene product expressed, wherein said inducing agent is a HDAC inhibitor, wherein the HDAC inhibitor is MS-275 or SB939, and wherein the subject is not treated with radiation therapy.

2. The method according to claim 1 , wherein said neoplasia associated with Epstein-Barr virus infection is a cancer associated with Epstein-Barr virus infection.

3. The method according to claim 1 , wherein said neoplasia is lymphoma.

4. The method of claim 1 , wherein the inducing agent induces expression of a viral gene product in a virus-infected cell of the subject, wherein the viral gene product is a viral enzyme, an oncogene or proto-oncogene, a transcription factor, a protease, a polymerase, a reverse transcriptase, a cell surface receptor, a structural protein, a major histocompatibility antigen, a growth factor, or a combination thereof.

5. The method of claim 4 , wherein the viral gene product is a viral enzyme selected from a thymidine kinase (TK) or protein kinase (PK).

6. The method of claim 1 wherein said inducing agent induces viral TK expression.

7. The method of claim 1 , wherein said inducing agent is administered at a dose of about 0.1 to about 2000 mg/kg/day or about 1 to about 100 mg/m 2 /day.

8. The method of claim 1 , wherein said anti-viral agent is selected from the group consisting of an interferon, an amino acid analog, a nucleoside analog, an integrase inhibitor, a protease inhibitor, a polymerase inhibitor, and a transcriptase inhibitor.

9. The method of claim 1 , wherein the anti-viral agent is a nucleoside analog selected from the group consisting of acyclovir (ACV), ganciclovir (GCV), famcyclovir, penciclovir (PCV), foscarnet, ribavirin, zalcitabine (ddC), zidovudine (AZT), stavudine (D4T), lamivudine (3TC), didanosine (ddl), cytarabine, dideoxyadenosine, edoxudine, floxuridine, idozuridine, inosine pranobex, 2′-deoxy-5-(methylamino)uridine, trifluridine or vidarabine.

10. The method of claim 1 , wherein the inducing agent is an HDAC inhibitor having inhibitory activity at 500 nM concentration.

11. The method of claim 1 , wherein the inducing agent is an HDAC inhibitor capable of inducing TK expression at 500 nM.

12. The method of claim 1 , wherein the inducing agent is an HDAC inhibitor capable of inducing TK expression within 6 hours of treatment.

13. The method of claim 1 , wherein a plasma level of the inducing agent in said subject is less than 5 μM.

14. The method of claim 1 , wherein said inducing agent is SB939.

15. The method of claim 1 , wherein said inducing agent and said anti-viral agent are administered for at least one cycle of therapy, said cycle comprising:

(i) administering the inducing agent and the anti-viral agent to the subject over a first period of time; and

(ii) continuing the administration of the anti-viral agent to the subject for a second period; wherein said second period represents the remainder of the cycle;

16. The method of claim 15 , wherein during the first period the anti-viral agent and inducing agent are administered in the same composition.

17. The method of claim 15 , wherein said first period of time is less than or equal to one-half of the length of the cycle.

18. The method of claim 17 , wherein said first period of time is less than or equal to about 5 days, and wherein said cycle is less than or equal to about 21 days.

19. The method of claim 1 , wherein said inducing agent is MS-275.

20. The method of claim 1 , wherein said anti-viral agent is ganciclovir.

21. The method of claim 1 , wherein said inducing agent is administered orally.